Floatz logo

Sotrastaurin

Richter Syndrome

James BlachlySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

57 Active assets in the Richter Syndrome cohort.

Asset / SponsorPhaseRating
Obinutuzumab
Christine Ryan
Phase 2BB
Ibrutinib
City of Hope Medical Center
Phase 2BB
Venetoclax
Northwestern University
Phase 2BB
Pirtobrutinib
SWOG Cancer Research Network
Phase 3BB
Cyclophosphamide
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

Sotrastaurin is also rated in:

uveal melanomaDormant
CCC
Indicative ·
54 / 100
View asset →
prolymphocytic leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
mantle cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →